AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

March 3, 2017 AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV. The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. Now, the two Big Pharmas will split R&D costs for MEDI8897, with AstraZeneca in charge of … Continue reading AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

Advertisements

Otsuka Pharmaceutical Acquiring Neurovance

Mar 3, 2017 In an effort to expand the portfolio of central nervous system-based therapies, Otsuka Pharmaceutical will acquire Neurovance Inc. in a transaction that could be worth as much as $250 million. As per the deal, Otsuka subsidiary Otsuka America Inc. will pay $100 million at closing and as much as $150 million based on approval … Continue reading Otsuka Pharmaceutical Acquiring Neurovance

Incyte turns to Penn for a collaboration on next-gen cancer combos

February 23, 2017 Incyte Corporation has signed off on a multi-year deal for collaborating with scientists at the University of Pennsylvania on its next-gen combos and cancer therapies. The Abramson Cancer Center of the university will take a lead role in looking at patient selection and combination opportunities as Incyte advances its plans to develop … Continue reading Incyte turns to Penn for a collaboration on next-gen cancer combos

Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Feb 15, 2017 Integra Lifesciences, a prominent medical device maker, has announced that it will acquire the Codman Neurosurgery business of Johnson & Johnson's (JNJ) for $1.05 billion. The Codman unit of JNJ includes a portfolio of medical devices focusing on advanced hydrocephalus, operative neurosurgery, and neuro-critical care, according to the company. During 2016, the acquired products generated approximately $370 million … Continue reading Integra Acquiring JNJ’s Codman Neurosurgery for $1.05 Billion

Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

February 10, 2017 Seat­tle Ge­net­ics has become the new flag car­rier for the solid tumor drug IMMU-132 of   Im­munomedics. In order to claim global rights on the drug, Seat­tle Ge­net­ics is pay­ing $300 mil­lion, and also com­mit­ting up to $1.7 bil­lion more in mile­stones. The biotech will now take the lead on a Phase III … Continue reading Seattle Genetics grabs tumor drug of Immunomedics in $2B deal

johnson & johnson logo

Johnson & Johnson to Purchase Actelion for $30 Billion

Jan 26, 2017 Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February. The companies said in a statement that J&J will pay $280 … Continue reading Johnson & Johnson to Purchase Actelion for $30 Billion

Eli Lilly Logo

Lilly to Acquire CoLucid Pharmaceuticals

Jan. 18, 2017 Eli Lilly and Company and CoLucid Pharmaceuticals, Inc. has announced an agreement for Lilly to acquire CoLucid for $46.50 per share or nearly $960 million. This all-cash transaction will enhance the existing portfolio of Lilly in pain management for migraine. The transaction is expected to close by the end of the first quarter of 2017. CoLucid Pharmaceuticals is a … Continue reading Lilly to Acquire CoLucid Pharmaceuticals

Lilly and Merck Expand Immuno-Oncology Collaboration

Jan. 11, 2017 Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS). Especially, the U.S. Food and Drug Administration (FDA) recently approved LARTRUVO … Continue reading Lilly and Merck Expand Immuno-Oncology Collaboration

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Jan. 9, 2017 Amgen and Immatics Biotechnologies, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement for developing next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Amgen's validated Bispecific T-cell Engager (BiTE®) technology with Immatics' world-leading XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with the goal … Continue reading Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Ipsen Acquiring Oncology Assets from Merrimack Pharmaceuticals

January 9, 2017 Ipsen will gain exclusive commercialization rights for the current and potential future of ONIVYDE indications in the U.S. ONIVYDE is an FDA-approved and clinically differentiated product for treating metastatic pancreatic cancer in adult patients. The transaction also includes the commercial and manufacturing infrastructure of Merrimack, and generic doxorubicin HCl liposome injection. The transaction … Continue reading Ipsen Acquiring Oncology Assets from Merrimack Pharmaceuticals